Viridian Therapeutics Inc. (VRDN)
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Viridian eye disease drug benefits chronic patients in late-stage trial
Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients.
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Viridian Therapeutics shares fall over 30% after trial data disappoints
Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company's REVEAL-1 trial in active thyroid eye disease (TED). The study, which tested the subcutaneous formulation of elegrobart, met its primary endpoint, signaling that the drug could gain approval.
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $0.81 per share a year ago.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $1.15 per share a year ago.
